 |
 |
|
17 January 2006 | Volume 144 Issue 2 | Pages 101-106
Background: Anecdotal case reports suggest tamoxifen as a possible treatment for retroperitoneal fibrosis, but a systematic assessment of its effect is not available.
Objective: To describe the course and outcomes of patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen.
Design: Prospective, consecutive series.
Setting: Single tertiary care referral center.
Patients: 19 patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen from April 1998 through April 2005.
Intervention: Tamoxifen, 20 mg orally twice daily.
Measurements: Clinical improvement, laboratory variables, and follow-up computed tomography (CT) and gallium scan findings.
Results: Fifteen patients reported substantial resolution of symptoms after a median treatment duration of 2.5 weeks. Erythrocyte sedimentation rate and C-reactive protein also improved. Gallium scanning at follow-up showed incomplete disappearance of pathologic gallium-67 activity. Repeated CT scanning showed slow but steady mass regression in 14 of 15 clinical responders. Five patients failed treatment, including 1 patient who improved clinically. Disease recurred in 1 patient who responded to reintroduction of tamoxifen. One patient developed reversible hepatitis.
Limitations: This small observational study did not have a control group.
Conclusion: Tamoxifen may be a viable therapeutic option in the treatment of retroperitoneal fibrosis.
Editors' Notes
Context
Contribution
Caution
Implications
—The Editors
Author and Article Information
From Albert Schweitzer Hospital, Dordrecht, the Netherlands.
Acknowledgment: The authors thank A.J.M. Cleophas, MD, PhD, and C. Siemes, MD, for their statistical advice.
Grant Support: None.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Eric F.H. van Bommel, MD, PhD, Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, P.O. Box 444, NL-3300 AK Dordrecht, the Netherlands; e-mail, e.f.h.vanbommel{at}asz.nl.
Current Author Addresses: Dr. van Bommel and Drs. Hendriksz, Huiskes, and Zeegers: Albert Schweitzer Hospital, P.O. Box 444, NL-3300 AK Dordrecht, the Netherlands.
Author Contributions: Conception and design: E.F.H. van Bommel.
Analysis and interpretation of the data: E.F.H. van Bommel, T.R. Hendriksz, A.W.L.C. Huiskes, A.G.M. Zeegers.
Drafting of the article: E.F.H. van Bommel.
Critical revision of the article for important intellectual content: E.F.H. van Bommel, T.R. Hendriksz, A.W.L.C. Huiskes, A.G.M. Zeegers.
Final approval of the article: E.F.H. van Bommel, T.R. Hendriksz, A.W.L.C. Huiskes, A.G.M. Zeegers.
Statistical expertise: E.F.H. van Bommel.
Collection and assembly of data: E.F.H. van Bommel, T.R. Hendriksz, A.W.L.C. Huiskes. ARTICLE
Brief Communication: Tamoxifen Therapy for Nonmalignant Retroperitoneal Fibrosis
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  E. van Bommel, S. van der Veer, T. Hendriksz, and G. Bleumink Persistent chronic peri-aortitis ('inflammatory aneurysm') after abdominal aortic aneurysm repair: systematic review of the literature Vascular Medicine, November 1, 2008; 13(4): 293 - 303. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Korzets, Y. Ori, D. Zevin, A. Chagnac, M. Herman, B. Rozen-Zvi, and U. Gafter A worrying thought--could there be a connection between encapsulating peritoneal sclerosis, tamoxifen and calciphylaxis? Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2975 - 2978. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vaglio, P. Greco, and C. Buzio Tamoxifen therapy for retroperitoneal fibrosis. Ann Intern Med, April 18, 2006; 144(8): 619 - 619. [Full Text] [PDF]
|
|
Read all Rapid Responses
Article
